Drawing First Blood

Drawing First Blood

Two experts to debate controversial topics in hematology and health care.

How Should We Treat Pregnant Women With Iron Deficiency?

Iron deficiency is prevalent among pregnant women, as maternal iron is used to supply the needs of the fetus and placenta, and additional iron...

Is Chronic Lymphocytic Leukemia Curable With Newer Agents?

Chronic lymphocytic leukemia (CLL) has long been considered an incurable disease. The goal of traditional frontline treatments is to minimize disease burden and allow...

Plasma or Recombinant Products for Hemophilia?

For the past half-century, plasma products have been the mainstay for the treatment of patients with hemophilia. In the 1950s, hematologists used large volumes...

Teaching Old Drugs New Tricks?

When the U.S. Food and Drug Administration (FDA) approved CPX-351 (a fixed combination of daunorubicin and cytarabine), it appeared that everything old was new...

Anticoagulation During Pregnancy

Because of physiologic changes during pregnancy, the risk of venous thromboembolism (VTE) is approximately five to 10 times higher than during non-pregnancy, and the...

Is MRD Testing Worthwhile in Myeloma?

With the clinically effective treatment regimens now available for myeloma, more patients can achieve deep and sustained responses. The ability to measure minimal residual...

Should Patients With Myelodysplastic Syndromes Undergo Transplant?

For patients with myelodysplastic syndromes (MDS), hematopoietic cell transplantation (HCT) is the only potentially curative option, but the rates of transplant-related morbidity and mortality...

To Test or Not to Test: Is Pharmacogenomic Testing for Warfarin Valuable?

Warfarin has been standard anticoagulation for more than 60 years, but the significant variability in both warfarin pharmacokinetics and pharmacodynamics makes achieving therapeutic drug...

Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A

Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For...

FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers?

Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this...
Advertisement

Current Issue

November 2018, Volume 4, Issue 13

This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.